Overview
Pamela dedicates her time to representing healthcare companies in transactional matters, guiding them to develop and engage in arrangements to support and achieve their business objectives. Pamela garners broad institutional knowledge of her clients and their goals, which she considers essential to providing the best legal counsel.
Through buy-side and sell-side acquisitions, divestitures, joint ventures, and other arrangements, Pamela guides health care providers to navigate transactions from the negotiation stage to completion. Pamela’s transactional experience spans across a wide range of healthcare businesses, including ambulatory surgery centers, radiology, fertility, dialysis services, dental, veterinary, pharmacy benefit management contracting, and micro-hospitals. She takes pride in working with clients and counterparties to pursue arrangements that will result in improved care for their patients.
Credentials
Education
Bar & Court Admissions
More
- Member, American Health Lawyers Association
- Member, American Bar Association
Related News & Insights
The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here
For more than a decade, nephrology practices have participated in Innovation Center kidney‑focused models—beginning with ESRD Seamless Care Organizations (“ESCOs”) under the Comprehensive ESRD Care (“CEC”) Model (2015–2021), followed by today’s Kidney Care Choices (“KCC”) Model (2022–2027). With KCC scheduled to end in December 2027, kidney care providers are approaching a critical transition point. The Long‑term Enhanced ACO Design (“LEAD”) Model, for which CMS released the Request for Applications (“RFA”) on March 31, 2026 (revised April 15, 2026), represents the next phase of CMS’s value‑based care strategy—but it differs fundamentally from the kidney‑specific models that preceded it.
Benesch Advises Preferred Vascular Group in Strategic Sale to Surgery Partners
Benesch is pleased to announce that it served as legal counsel to Preferred Vascular Group (PVG) in its recent acquisition …
LEAD vs. ACO REACH–What’s Changing and Why the LEAD Model Matters for ACOs and Participating Providers
The Long-term Enhanced ACO Design (“LEAD”) model is Centers for Medicare & Medicaid Services Innovation Center’s (Innovation Center) newly announced successor to the ACO Realizing Equity, Access, and Community Health (REACH) model. While LEAD retains the core framework of two-sided risk and population-based payments, it introduces critical changes aimed at making the program more sustainable, inclusive and effective to foster longer term administration for providers.
CMS Puts Specialists in the Game with LEAD
For years, many specialist physicians have watched Medicare’s ACO programs from the sidelines, uncertain how to participate in models historically centered on primary care providers. The Long-term Enhanced ACO Design (LEAD) Model marks a fundamental shift in this dynamic.